.Pharmacolibrary.Drugs.S_SensoryOrgans.S01B_AntiinflammatoryAgents.S01BC02_Oxyphenbutazone.Oxyphenbutazone .Pharmacolibrary.Drugs.S_SensoryOrgans.S01B_AntiinflammatoryAgents.S01BC02_Oxyphenbutazone.Oxyphenbutazone| name: | Oxyphenbutazone |
| ATC code: | S01BC02 | route: | oral |
| n-compartments | 1 |
Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID) formerly used for its analgesic and anti-inflammatory properties, primarily in the treatment of rheumatoid arthritis, ankylosing spondylitis, and other musculoskeletal conditions. It is a metabolite of phenylbutazone. Due to serious adverse effects including bone marrow suppression and agranulocytosis, oxyphenbutazone has been withdrawn or severely restricted in many countries and is not commonly used today.
Estimated pharmacokinetic parameters for adults assuming typical NSAID PK characteristics. No recent or accessible peer-reviewed publication directly reports detailed PK model for oxyphenbutazone in humans.
Chay, S, et al., & Yocum, J (1984). Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses. Journal of veterinary pharmacology and therapeutics 7(4) 265–276. DOI:10.1111/j.1365-2885.1984.tb00911.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/6512917
Brouwers, JR, & de Smet, PA (1994). Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Clinical pharmacokinetics 27(6) 462–485. DOI:10.2165/00003088-199427060-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7882636
Tobin, T, et al., & Lees, P (1986). Phenylbutazone in the horse: a review. Journal of veterinary pharmacology and therapeutics 9(1) 1–25. DOI:10.1111/j.1365-2885.1986.tb00008.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/3517382